8-K
filed May 19, 2025, 7:59 PM ET
ticker PTIX
CIK 0001022899
M&A
confidence high
sentiment neutral
materiality 0.90
Protagenic Therapeutics, Inc.new (PTIX): M&A transaction — Protagenic Therapeutics acquires Phytanix Bio in share exchange, appoints new CEO and directors
Protagenic Therapeutics, Inc.new
- Acquired 100% of Phytanix Bio common shares from Alterola Biotech and EMC2 Capital as of May 15, 2025
- Issued 117,690 common shares, 5,705 Series C Preferred, 950,000 Series C-1 Preferred, and 20,000 Series D Preferred to Phytanix stockholders
- Appointed Barrett Evans as President and CEO, Colin Stott as COO and director, and Jennifer Chao as director; Andrew Slee promoted to Chief Development Officer
- Resignations of directors Khalil Barrage, Tim Wright, and Robert Stein effective immediately before closing
- Filed certificates of designation for Series C and C-1 Non-Voting Convertible Preferred Stock on May 15, 2025
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Khalil Barrage resigned as Director at Protagenic Therapeutics, Inc.new.
- Action
- resigned
- Role
- Director
Exact text from the filing
accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Colin Stott was appointed as Chief Operating Officer at Protagenic Therapeutics, Inc.new.
- Action
- appointed
- Role
- Chief Operating Officer
Exact text from the filing
Colin Stott as Chief Operating Officer and as a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Colin Stott was appointed as Director at Protagenic Therapeutics, Inc.new.
- Action
- appointed
- Role
- Director
Exact text from the filing
Colin Stott as Chief Operating Officer and as a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jennifer Chao was appointed as Director at Protagenic Therapeutics, Inc.new.
- Action
- appointed
- Role
- Director
Exact text from the filing
Jennifer Chao as a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Barrett Evans was appointed as President and Chief Executive Officer at Protagenic Therapeutics, Inc.new.
- Action
- appointed
- Role
- President and Chief Executive Officer
Exact text from the filing
appointed Barrett Evans as President and Chief Executive Officer, and a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Barrett Evans was appointed as Director at Protagenic Therapeutics, Inc.new.
- Action
- appointed
- Role
- Director
Exact text from the filing
appointed Barrett Evans as President and Chief Executive Officer, and a director of the Company
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Stein resigned as Director at Protagenic Therapeutics, Inc.new.
- Action
- resigned
- Role
- Director
Exact text from the filing
accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tim Wright resigned as Director at Protagenic Therapeutics, Inc.new.
- Action
- resigned
- Role
- Director
Exact text from the filing
accepted the resignation of Khalil Barrage, Tim Wright and Robert Stein, from the Board, effective as of immediately prior to the Closing on May 15, 2025
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Andrew Slee changed role as Chief Development Officer at Protagenic Therapeutics, Inc.new.
- Action
- promoted
- Role
- Chief Development Officer
Exact text from the filing
promoted Andrew Slee from his prior role of Chief Operating Officer to the Company’s Chief Development Officer, effective immediately upon the Closing on May 15, 2025
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Protagenic Therapeutics, Inc.new: Filed Series C-1 Certificate of Designation creating another new series of preferred stock (effective 2025-05-15).
- Change
- charter amendment
- Effective
- 2025-05-15
Exact text from the filing
On May 15, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series C-1 Non-Voting Convertible Preferred Stock (the “Series C-1 Certificate of Designation”) with the Secretary of State of the State of Delaware
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Protagenic Therapeutics, Inc.new: Filed Series C Certificate of Designation creating a new series of preferred stock (effective 2025-05-15).
- Change
- charter amendment
- Effective
- 2025-05-15
Exact text from the filing
On May 15, 2025, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of the Series C Non-Voting Convertible Preferred Stock (the “Series C Certificate of Designation”) with the Secretary of State of the State of Delaware
View on SEC.gov
M&A Transactions
SEC 8-K Item 2.01/5.01
confidence 0.9
Protagenic Therapeutics, Inc.new completed an acquisition involving Alterola Biotech Inc., EMC2 Capital LLC, and the Preferred Stockholders (closed 2025-05-16).
- Action
- acquisition
- Counterparty
- Alterola Biotech Inc., EMC2 Capital LLC, and the Preferred Stockholders
- Closing
- 2025-05-16
Exact text from the filing
On May 16, 2025, the Company completed its business combination with Alterola, EMC2, and the Preferred Stockholders.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.